FUSION PHARMACEUTICALS INC's ticker is FUSN and the CUSIP is 36118A100. A total of 35 filers reported holding FUSION PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,119,202 | -44.3% | 3,122,770 | 0.0% | 0.17% | -34.8% |
| Q2 2023 | $14,583,336 | +23.9% | 3,122,770 | 0.0% | 0.26% | +14.3% |
| Q1 2023 | $11,772,843 | +15.9% | 3,122,770 | -3.2% | 0.23% | +19.1% |
| Q4 2022 | $10,158,026 | +4.6% | 3,224,770 | 0.0% | 0.19% | +7.8% |
| Q3 2022 | $9,707,000 | +20.9% | 3,224,770 | 0.0% | 0.18% | +23.3% |
| Q2 2022 | $8,030,000 | -68.0% | 3,224,770 | 0.0% | 0.15% | -64.0% |
| Q1 2022 | $25,056,000 | +86.3% | 3,224,770 | 0.0% | 0.41% | +134.7% |
| Q4 2021 | $13,447,000 | -47.3% | 3,224,770 | 0.0% | 0.17% | -38.4% |
| Q3 2021 | $25,540,000 | -2.0% | 3,224,770 | 0.0% | 0.28% | +6.4% |
| Q2 2021 | $26,056,000 | -24.6% | 3,224,770 | 0.0% | 0.26% | -18.3% |
| Q1 2021 | $34,570,000 | -8.8% | 3,224,770 | 0.0% | 0.32% | -2.7% |
| Q4 2020 | $37,891,000 | -2.2% | 3,224,770 | 0.0% | 0.33% | -31.8% |
| Q3 2020 | $38,762,000 | -31.2% | 3,224,770 | 0.0% | 0.49% | -38.6% |
| Q2 2020 | $56,337,000 | – | 3,224,770 | – | 0.79% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,670,516 | $9,140,000 | 2.34% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,560,982 | $3,887,000 | 1.96% |
| ADAMS STREET PARTNERS LLC | 2,947,809 | $7,340,000 | 1.91% |
| Sio Capital Management, LLC | 260,448 | $649,000 | 0.24% |
| Orbimed Advisors | 3,224,770 | $8,030,000 | 0.15% |
| Artal Group S.A. | 750,000 | $1,868,000 | 0.10% |
| TPG GP A, LLC | 2,551,794 | $6,354,000 | 0.10% |
| Perceptive Advisors | 1,052,445 | $2,621,000 | 0.08% |
| Rock Springs Capital Management LP | 809,854 | $2,017,000 | 0.06% |
| FEDERATED HERMES, INC. | 3,124,100 | $7,779,000 | 0.02% |